State Medicaid application deadline for the BALANCE Model passes

The application window for states to join the BALANCE Model, a federal program meant to expand Medicaid coverage of GLP-1 drugs for obesity, closed on July 31, 2026 ^[1]. As of mid-August 2026, the Centers for Medicare and Medicaid Services' own model page still listed the number of participants as not applicable and named no participating state ^[2].

The BALANCE Model, short for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, is a Center for Medicare and Medicaid Innovation program that lets CMS negotiate drug prices with manufacturers on behalf of states and, separately, Medicare Part D plans ^[1][2]. Participation is voluntary for drugmakers, states, and health plans, and the model's timeline shows manufacturers had until January 8, 2026 to apply, followed by a pre-implementation period running into early February to set the terms of participation agreements ^[1]. States could then join on a rolling basis starting May 1, 2026, with the July 31 deadline as the cutoff for that state application window, and the model is scheduled to run through December 31, 2031 for states that do sign on ^[1].

Right now, only 13 states cover GLP-1s for obesity through Medicaid on their own, down from 16 states in 2025, a drop that KFF says likely reflects the cost of coverage along with state budget pressures and federal funding cuts ^[1]. Medicaid spending on GLP-1 drugs for all approved uses, not just obesity, already reached $8.6 billion in 2024 on 8.4 million prescriptions, up from under $1 billion in 2019 ^[1]. Under current law, states are not required to cover weight-loss drugs through Medicaid, unlike other FDA-approved uses such as type 2 diabetes, which they must cover ^[1].

The BALANCE Model timeline for Medicare's parallel track has already slipped. CMS announced on April 21, 2026 an indefinite delay of the BALANCE Model in Medicare Part D, while extending a separate, short-term program called the Medicare GLP-1 Bridge through the end of 2027 instead of stopping it in December 2026 as originally planned ^[1]. That Bridge program gives Medicare Part D beneficiaries who meet certain BMI and clinical criteria access to specific obesity drugs, including Foundayo, Wegovy, and the KwikPen formulation of Zepbound, at a $50 monthly copay starting July 1, 2026 ^[1].

Why it matters for patients

For people on Medicaid, the practical effect of this deadline passing without a named state is that nothing has changed yet. Coverage for obesity drugs under Medicaid still depends on which state a person lives in, and only 13 states currently cover these drugs for weight loss on their own, without the BALANCE Model ^[1]. Whether any of those states, or others, will use the federal negotiating power to add or expand coverage is not yet known from CMS's public data as of mid-August 2026 ^[2].

Medicare beneficiaries are on a different track. They are not waiting on state Medicaid decisions, because the Medicare GLP-1 Bridge already began covering select obesity drugs on July 1, 2026, separate from the delayed Medicare side of the BALANCE Model ^[1]. That program runs through December 31, 2027, with a $50 monthly copay for those who meet the eligibility criteria ^[1].

For Medicaid enrollees, the size of the gap between the federal offer and actual state uptake matters because participation in the BALANCE Model is entirely voluntary, and states with strained budgets may weigh the cost of expanding obesity drug coverage even at negotiated prices ^[1][2].

What happens next

CMS has not yet published a list of participating states following the July 31, 2026 deadline ^[2]. If states do join on a rolling basis, the model is set to run through December 31, 2031 ^[1]. The separate Medicare GLP-1 Bridge program continues through December 31, 2027, regardless of the Medicaid state participation outcome ^[1].